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Background:  Sarcoplasmic reticulum (SR) calcium cycling is abnormal in heart failure (HF) and leads to calcium overload. We previously showed 
that long-term monotherapy with Ivabradine (IVA), a selective and specific inhibitor of the cardiac pacemaker current Iƒ, improves LV function in 
dogs with coronary microembolization-induced HF. This study tested the hypothesis that improved LV function with IVA is associated with improved 
SR calcium cycling.
Methods:  Studies were performed in LV tissue from 24 HF dogs randomized to 3 months monotherapy with high dose (HD) IVA (30 mg Bid, n=8), 
low dose (LD) IVA (15 mg Bid, n=8) or to no therapy (Placebo, n=8). LV tissue from 6 normal (NL) dogs was used for comparison. Vmax of oxalate-
dependent SR calcium uptake (Vsrcu) and Vmax of thapsigargin sensitive SR calcium ATPase activity (Vsrcaa) were measured in LV tissue membrane 
fractions. SERCA2a protein level normalized to calsequestrin (CSQ) was measured by Western blots.
Results:  Heart rate (HR) decreased 12±2 bpm from PRE to POST therapy in HD-IVA, 8±2 bpm in LD IVA and 4±3 bpm in Placebo. Vsrcu, Vsrcaa, 
and SERCA2a/CSQ decreased significantly in Placebo dogs compared to NL dogs. Compared to Placebo, treatment with IVA increased Vsrcu and 
Vsrcaa in a dose-dependent manner. SERCa2a/CSQ increased to the same extent with both IVA doses.
Conclusions:  HR reduction with IVA is associated with improved SR calcium cycling. This finding suggests that therapy with IVA can mitigate the 
adverse consequences of calcium overload in HF.
Table of Results (Mean ± STD)
NL Placebo LD-IVA HD-IVA
Vsrcu (μml 45Ca2+ sequestered/min/mg protein) 27.3 ± 1.8 13.0 ± 1.3* 18.6 ± 2.1*† 21.5 ± 1.7*†‡
Vsrcaa (μmol Pi released/min/mg protein) 0.34 ± 0.01 0.26 ± 0.01* 0.29 ± 0.01*† 0.32 ± 0.01*†‡
SERCA2a/CSQ 1.04 ± 0.22 0.60 ± 0.06* 0.90 ± 0.16† 0.89 ± 0.19†
*=p<0.05 vs. NL; †=p<0.05 vs. Placebo; ‡=p<0.05 vs. LD-IVA
